Asset Details
Do you wish to reserve the book?
Comparison of oral anticoagulation and antiplatelet therapy during the midperiod after percutaneous left atrial appendage closure
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Comparison of oral anticoagulation and antiplatelet therapy during the midperiod after percutaneous left atrial appendage closure
Do you wish to request the book?
Comparison of oral anticoagulation and antiplatelet therapy during the midperiod after percutaneous left atrial appendage closure
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Comparison of oral anticoagulation and antiplatelet therapy during the midperiod after percutaneous left atrial appendage closure
2025
Overview
Background and aimThere is a lack of evidence comparing anticoagulation and antiplatelet therapy during the midperiod time after left atrial appendage closure (LAAC) in clinical practice (the “early period” is defined as “45 days” after LAAC for a single procedure of LAAC and “3 months” after LAAC for a combined therapy of LAAC and catheter ablation; we defined the time between the “early period” and 6 months following LAAC as the “midperiod”). Our study aims to assess the safety and effectiveness of different anticoagulant therapies in patients undergoing the LAAC procedure with the WATCHMAN device during the midperiod after LAAC implantation in clinical practice.MethodsThis prospective, single-center cohort study included 374 consecutive patients undergoing percutaneous LAAC with the Watchman device. Patients were divided into two groups: oral anticoagulation (OAC) and antiplatelet therapy (APT). The primary composite endpoint was cardiac mortality, ischemic stroke/ transient ischemic attacks/systemic embolism, and major bleeding events after 6 months following the procedure. The secondary endpoints are cardiovascular death, device-related thrombosis (DRT) events, and each component of the primary endpoint.ResultsThe risk of the primary outcome in the APT group and the OAC group had no statistical difference in multivariable Cox regression (adjusted HR = 0.76; 95% CI: 0.40–1.49; P = 0.447). The secondary endpoints—including cardiac mortality, cardiovascular death, ischemic stroke/systemic embolism, major bleeding events, and DRT events—did not statistically differ between the two groups.ConclusionDuring the midperiod time after LAAC implantation with the WATCHMAN device, OAC therapy may demonstrate similar safety and efficacy compared with dual antiplatelet therapy.
Publisher
Frontiers Media SA
Subject
We currently cannot retrieve any items related to this title. Kindly check back at a later time.